Investigator Laboratories

FRRBP Investigator laboratories

Allen lab:

Dr. Allen's lab focuses on understanding the basic science mechanisms by which pharmacological ascorbate can selectively act as a pro-oxidant in brain and lung cancer vs. normal cells, for the purpose of developing novel combined modality chemo-radio-therapies.

Buettner lab:

Our labs interest is in exploring the fundamental chemistry and biochemistry of vitamins C and E. Nitric Oxide is being investigated (NIH funded) as an important membrane antioxidant in cells and tissue. We hypothesize that it is as important as Vitamin E.

Byrne lab:

Byrne Lab is driven by our long-term interest: developing transformative technologies to improve patient care. Bridging the disciplines of biomedical engineering and oncology, our lab strives toward innovation. The Byrne Lab actively collaborates with other labs and investigators both at the University of Iowa and outside the campus.

Caster lab:

The theme of our research is to identify novel ways of improving the therapeutic index of chemoradiotherapy; i.e. improving treatment the efficacy of chemoradiation and/or minimizing its toxicity. 

Coleman lab:

The Coleman laboratory is focused on translational research of treatments to prevent musculoskeletal disorders that result from injury, whether after a car crash or exposure to therapeutic doses of radiation during cancer treatment.  Research revolves around the principle that mitochondria are the major drivers of oxidative stress in many cell types, including chondrocytes in articular cartilage.

Cullen lab:

Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in the United States and is increasing in incidence. Intravenous ascorbate (high dose vitamin C), but not oral ascorbate, produces high plasma concentrations, which are in the range that are cytotoxic to tumor cells.

Goswami lab:

Dr. Goswami's laboratory is pursuing basic science research in the field of free radical biology of the mammalian cell cycle, aging and cancer. His laboratory first reported the presence of a “redox cycle” within the mammalian cell cycle that integrates cellular metabolism to cell cycle progression.

Griguer lab:

The overall goal of our lab is to perform research that contributes to a better understanding of metabolic vulnerabilities in brain cancer and the associated therapeutic opportunities.

Schultz lab:

Dr. Schultz's research interests involve the development of synthetic-bioactive molecular targeting vectors for imaging and therapy of cancer. Molecular targeting involves identification of G-protein coupled receptors and other cell surface antigens and the development of targeting vectors that selectively bind to these antigens.

Spitz lab:

The long-term goal of this laboratory’s efforts are to use a basic science understanding of the mechanisms associated with free radical biology to elucidate novel methods for manipulating clinically significant outcomes in areas of medicine relevant to cancer biology and degenerative diseases associated with aging.